RecruitingNot applicableNCT07111936

Evaluating the Impact of CONNECT in a Multilingual Population

This study aims to broaden the reach of the lung cancer screening (LCS) CONNECT program (NCT04149249, NCT06213532), by developing a version of the program to be available to multilingual communities. The CONNECT program encourages individuals who are undergoing lung cancer screening to also quit smoking by providing a personalized program which includes a video doctor with personalized responses, text message and telephone call support and connection with a pharmacist to assist in obtaining nicotine replacement medication. This clinical trial will develop and ultimately test how well the CONNECT Multilingual (CONNECT ML) program works to improve smoking cessation among current adult smokers within the Spanish and Cantonese speaking communities.

Checked against the public recordLast updated Aug 13, 2026 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations1
SponsorUniversity of California, San Francisco
01
Study overview

What this study is about

Purpose
Prevention
Study type
Interventional
Phase
Not applicable
Sponsor
University of California, San Francisco
Interventions being studied
Behavioral: CONNECT Intervention for multilingual populations; Other: Saliva Sample; Other: Interview
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Age 50-80 years old. * Current smokers defined at smoking at least one cigarette in past 7 days AND eligible for lung cancer screening (LCS) based on smoking history (\>=20 pack year history) * California (CA) residents * Able to understand and comply with study procedures for the entire length of the study. * Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: * Non-smokers. * Individuals with a diagnosis of lung cancer. * Individuals receiving hospice care. * Individuals whose providers do not think that they should participate (e.g., psychiatric illness or significant cognitive impairment that would impede the individuals ability to participate). * Hearing and/or vision disabilities that would prevent participants from adequately receiving treatment components such as video or telephone counseling.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of California San FranciscoSan Francisco, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 13, 2026. Always confirm current availability with the study team.

View original record ↗